RE-MIND2: observational study comparing tafasitamab+lenalidomide to available therapies in R/R DLBCL

Long-term follow-up of tafasitamab and lenalidomide in R/R DLBCLПодробнее

Long-term outcomes with tafasitamab plus lenalidomide for R/R DLBCLПодробнее

First-MIND: Phase Ib study of R-CHOP + tafasitamab ± lenalidomide in newly diagnosed DLCBLПодробнее

frontMIND: Tafasitamab + lenalidomide + R-CHOP vs R-CHOP in high-intermediate & high-risk DLBCLПодробнее

Tafasitamab Plus Lenalidomide Approval Generates Excitement for Second-Line DLBCLПодробнее

L-MIND Study: R/R DLBCLПодробнее

The use of tafasitamab and lenalidomide in R/R DLBCLПодробнее

frontMIND: tafasitamab + lenalidomide + R-CHOP vs R-CHOP in newly diagnosed high-risk DLBCLПодробнее

Tafasitamab-lenalidomide in R/R DLBCL: clinical trial results and real-world dataПодробнее

FrontMIND: tafasitamab + lenalidomide + R-CHOP vs R-CHOP for newly diagnosed high-risk DLBCLПодробнее

Updates on tafasitamab for the treatment of DLBCLПодробнее

Dr. Kahl on the Utility of Tafasitamab/Lenalidomide in DLBCLПодробнее

Tafasitamab in DLBCLПодробнее

Real-world efficacy of tafasitamab + lenalidomide in R/R DLBCL & the importance of patient selectionПодробнее

Re-MIND Versus L-MIND RegimenПодробнее

The role of tafasitamab in the lymphoma treatment landscape & promising results from clinical trialsПодробнее

The use of tafasitamab in DLBCLПодробнее

Dr. Kahl on Findings From the L-MIND Study With Tafasitamab in DLBCLПодробнее

The latest updates on tafasitamab in DLBCLПодробнее